Comparative effectiveness of H7N9 vaccines in healthy individuals

Dan Zheng; Feixia Gao; Cheng Zhao; Yahong Ding; Yemin Cao; Tianhan Yang; Xuesong Xu; Ze Chen

doi:10.1080/21645515.2018.1515454

Comparative effectiveness of H7N9 vaccines in healthy individuals

Hum Vaccin Immunother. 2019;15(1):80-90. doi: 10.1080/21645515.2018.1515454. Epub 2018 Sep 14.

Authors

Dan Zheng^{1

2

3}, Feixia Gao¹, Cheng Zhao^{2

3}, Yahong Ding¹, Yemin Cao^{2

3}, Tianhan Yang¹, Xuesong Xu⁴, Ze Chen¹

Affiliations

¹ a Department of Research and Development , Shanghai Institute of Biological Products , Shanghai , China.
² b Shanghai TCM-Integrated Hospital , Shanghai University of Traditional Chinese Medicine , Shanghai , China.
³ c Department of Vascular Disease , Shanghai TCM-Integrated Institute of Vascular Disease , Shanghai , China.
⁴ d Huadong Hospital Affiliated to Fudan University , Shanghai , China.

Abstract

Background: Avian H7N9 influenza viruses possess a potential pandemic threat to public health worldwide, and have caused severe infection and high mortality in humans. A series of clinical trials of H7N9 vaccines have been completed. Meta-analyses need to be performed to assess the immunogenicity and safety of H7N9 vaccines.

Methods: Database research with defined selection criteria was conducted in PubMed, Cochrane Central Register of Controlled Trials, the World Health Organization's International Clinical Trials Registry Platform, ClinicalTrials.gov, etc. Data from randomized clinical trials regarding the immunogenicity and safety of H7N9 vaccines were collected and meta-analyzed.

Results: For non-adjuvanted H7N9 vaccines, high dose formulations induced limited immunogenicity and increased the risk of local and systemic adverse events, simultaneously. For adjuvanted H7N9 vaccines, on the one hand, ISCOMATRIX, MF59, AS03 and aluminium adjuvants applied in H7N9 vaccines could improve immune responses effectively, and non-aluminium adjuvants had superior performance in saving vaccine dose; on the other hand, aluminium adjuvant had the advantages of safety amongst these adjuvants applied in H7N9 vaccines.

Conclusion: H7N9 influenza vaccines with adjuvant might represent the optimal available option in an influenza pandemic, at present.

Keywords: H7N9 vaccine; adjuvant; immunogenicity; meta-analysis; safety.

Publication types

Comparative Study
Meta-Analysis
Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / administration & dosage
Adjuvants, Immunologic / standards
Female
Humans
Immunogenicity, Vaccine
Influenza A Virus, H7N9 Subtype*
Influenza Vaccines / immunology*
Influenza Vaccines / standards*
Influenza, Human / prevention & control*
Male
Randomized Controlled Trials as Topic

Substances

Adjuvants, Immunologic
Influenza Vaccines

Grants and funding

This work was supported by the Shanghai Science and Technology Support Program, China [grant number 15431906500 and 17431901300] and National Key Subject of Drug Innovation [grant number 2015ZX09101044].